Drug
QLS32015
QLS32015 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph early_phase_1
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
unknown1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
unknown125%
recruiting250%
not_yet_recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_3
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07138209
recruitingphase_2
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07018050
not_yet_recruitingearly_phase_1
A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
NCT07185477
unknownphase_1
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
NCT05920876
Clinical Trials (4)
Showing 4 of 4 trials
NCT07138209Phase 3
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07018050Phase 2
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07185477Early Phase 1
A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
NCT05920876Phase 1
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4